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better and more attractive to Polish authors, par‑
ticularly, young investigators. The journal sup‑
ports research done by medical students by award‑
ing the best student paper prize. In the current is‑
sue, 3 articles have been prepared by researchers 
at the very beginning of their scientific career.1‑3 
Proportionally to the IF, the number of submit‑
ted manuscripts has increased in the Pol Arch 
Med Wewn like in other journals. I believe that 
the quality of our journal will improve at a sim‑
ilar speed.
I will now provide a short overview of the most 
cited papers published in the Pol Arch Med Wewn, 
which largely contributed to the  current IF 
(TABLE 2).4‑15 Moreover, based on an online search 
(Web of Science), I selected papers published 
in 2014 felt to be worth appreciating based on 
the number of citations they received until June 
30, 2015 (TABLE 3).16‑19 Review articles are general‑
ly cited more frequently than typical research ar‑
ticles. However, not in all journals. For example, 
in the Pol Arch Med Wewn, 38% of the citations 
from 2014 came from reviews, while the largest 
share of 62% represented citations of original 
studies, which highlights the scientific value of 
the articles accepted for publication in the years 
2012–2013. Moreover, the Pol Arch Med Wewn 
does not publish clinical practice guidelines sup‑
ported by scientific societies or consensus docu‑
ments such as position papers. On the other hand, 
24% of the papers from 2012 and 2013 included 
in the denominator of the 2014 IF were not cited 
even once in 2014. This proportion, article types, 
and authors will be analyzed to draw conclusions 
that may provide us with much needed guidance 
while evaluating the increasing number of new 
submissions. In light of the above data, the pres‑
ent IF is impressive.
In 2014, some new initiatives were started 
in the Pol Arch Med Wewn, including the intro‑
duction of the Controversies in Medicine sec‑
tion. A paper by Peter Gøtzsche20 published in 
the November 2014 issue has attracted particular 
The journal’s impact factor published in 2015 by 
Thomson Reuters is a measure of the number of 
times an “average article” from the year 2012 or 
2013 was cited in 2014. We are happy to announce 
that the impact factor (IF) of the Pol Arch Med 
Wewn increased to 2.121 in 2014 (FIGURE 1). This 
index provides quantitative evidence for the posi‑
tion of the Pol Arch Med Wewn in relation to oth‑
er journals, especially those in the same catego‑
ry, and also in comparison to several Polish bio‑
medical journals (TABLE 1). I strongly believe that 
our journal is likely to achieve an IF of about 2.5 
in the near future.
We feel that this is a good sign that although 
we still have a Polish title and most our papers 
are submitted by Polish authors, international 
scientific and clinical communities appear to in‑
creasingly value our content.
We sincerely thank all our authors, review‑
ers, members of the scientific boards, and read‑
ers who helped us achieve this year’s IF. We have 
come a long way in a short span of time thanks 
to your continued support.
The journal’s acceptance rate in 2014 was 24%. 
In the first 6 months of 2015, the journal’s web‑
site has had an average of 5000 visitors a month, 
which is a similar value to that obtained from Jan‑
uary to June 2014. Editorial processing times re‑
main competitive. The average processing time in 
2015 is 20 days from submission to the first de‑
cision and 39 days since submission to the final 
decision to accept or reject an article. The aver‑
age time for an individual article to appear online 
is 4.1 days since acceptance. In the era of global‑
ization, the sooner the better in terms of shar‑
ing research data with other investigators and 
readers. Therefore, we are extremely proud of 
these numbers.
The best papers authored by Poles are always 
submitted first to journals based in the United 
States and Western European countries. I believe 
that it is up to the Polish Society of Internal Med‑
icine and our editorial team to make the journal 
Correspondence to:
Prof. Anetta Undas, MD, PhD, Instytut 
Kardiologii, Uniwersytet Jagielloński, 
Collegium Medicum, ul. Prądnicka 80, 
31-202 Kraków, Poland,  
phone: +48 12 614 30 04,  
fax: +48 12 423 39 00,  
e-mail: mmundas@cyf -kr.edu.pl
Received: July 16, 2015.
Accepted: July 16, 2015.
Conflict of interest: none declared.
Pol Arch Med Wewn. 2015; 
125 (7-8): 493-496
Copyright by Medycyna Praktyczna, 
Kraków 2015
EDITORIAL
A new impact factor: what we are proud 
of and where we are heading
Anetta Undas
Editor‑in‑Chief, Polish Archives of Internal Medicine
POLSKIE ARCHIWUM MEDYCYNY WEWNĘTRZNEJ 2015; 125 (7-8)494
and methodological challenges in clinical stud‑
ies, which will be published in Polish in Novem‑
ber 2015. Another special issue, scheduled to be 
interest, especially among the Polish reader‑
ship. Please also pay attention to our upcom‑
ing special issue on Cochrane Collaboration 
FIGURE 1 Impact 
factor of the Pol Arch 
Med Wewn in the years  
2011–2014
TABLE 1 Polish medical journals—changes in impact factor in 2013 and 2014
Abbreviated journal title 2014 2013
ARCH IMMUNOL THER EX ↑ 3.176 2.818
J PHYSIOL PHARMACOL ↓ 2.386 2.720
POL ARCH MED WEWN ↑ 2.121 2.052
ARCH MED SCI ↑ 2.030 1.890
PHARMACOL REP ↓ 1.928 2.165
FOLIA NEUROPATHOL ↓ 1.568 1.667
HERED CANCER CLIN PR ↓ 1.472 2.103
TRANSL NEUROSCI ↑ 1.319 0.716
J CONTEMP BRACHYTHER ↑ 1.284 –
ANN TRANSPL ↓ 1.261 1.430
POL J PATHOL ↑ 1.128 0.832
ADV MED SCI-POLAND ↑ 1.105 0.964
ADV CLIN EXP MED ↑ 1.095 0.333
CARDIOL J ↓ 1.062 1.215
ENDOKRYNOL POL ↓ 0.993 1.208
POSTEP DERM ALERGOL ↑ 0.845 –
PSYCHIATR POL ↓ 0.733 0.753
NEUROL NEUROCHIR POL ↑ 0.641 0.537
GINEKOL POL ↓ 0.601 0.675
POSTEP HIG MED DOSW ↓ 0.573 0.633
KARDIOL POL ↑ 0.539 0.519
CENT EUR J IMMUNOL ↓ 0.280 0.358
CENT EUR J MED ↓ 0.153 0.209
POSTEP KARDIOL INTER ↑ 0.148 0.066
PRZ GASTROENTEROL ↓ – 0.375
VIDEOSURGERY MINIINV ↓ – 1.092
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of Internal Medicine in May 2015. The page fees 
for accepted manuscripts will be charged start‑
ing from September 1, 2015. The fees will be as 
follows: 2000 PLN (500 Euro) for original and 
unsolicited review papers, 1500 PLN (300 Euro) 
for research letters, and 1000 PLN (250 Euro) for 
clinical images, with no fee for letters to the edi‑
tor or invited review articles (see our current In‑
structions for authors). There are no fees for ac‑
cess to published papers (open access) or color 
fees. Despite support from the Polish Ministry 
of Science and Higher Education, the publisher, 
Medycyna Praktyczna, had to cover a substantial 
proportion of the journal’s costs. Now we hope 
that several new initiatives aimed at improving 
the quality of and promoting our journal will be 
launched in 2016.
Running the  journal would never have 
been possible without the help of the vice edi‑
tor‑in‑chief, Dr. Grzegorz Gajos. Special thanks 
go to the managing editor, Małgorzata Wiesner.
Looking towards the future, it is hoped that 
publication in the Pol Arch Med Wewn will soon 
be in itself an honor and recognition of a paper’s 
value, especially for Polish researchers. I sincere‑
ly hope that we will all enjoy reading interesting, 
diverse studies published in the subsequent is‑
sues of the Pol Arch Med Wewn. To achieve this, 
published at the beginning of 2016, will present 
the fundamentals of biostatistics for young in‑
vestigators. Without the first‑rate methodology 
and statistical analysis, no good papers will be 
published in the Pol Arch Med Wewn like in oth‑
er journals.
We also acknowledge the immense work of our 
reviewers. The most hard‑working reviewers in 
2014 are listed in TABLE 4.
A major change regarding publication fees was 
approved by the authorities of the Polish Society 
TABLE 2 Most cited articles published in 2012 and 2013
No. Article (2012–2013) Title Citations in 2014
1 Lipinski and Pretorius4 Novel pathway of iron-induced blood coagulation: implications for diabetes mellitus  
and its complications
14
2 Sarr5 2012 revision of the Atlanta classification of acute pancreatitis 8
3 Okraska‑Bylica et al.6 Altered fibrin clot properties in patients with premature peripheral artery disease 8
4 Ulasli et al.7 Mean platelet volume as an inflammatory marker in acute exacerbation of chronic 
obstructive pulmonary disease
7
5 Kwaśny‑Krochin et al.8 Plasma asymmetric dimethylarginine in active rheumatoid arthritis: links with oxidative 
stress and inflammation
7
6 Wilk et al.9 Endothelial function assessment in atherosclerosis: comparison of brachial artery 
flow-mediated vasodilation and peripheral arterial tonometry
7
7 Urbankowski et al.10 Th1/Th2/Th17 ‑related cytokines in the bronchoalveolar lavage fluid of patients with 
sarcoidosis: association with smoking
7
8 Kleinegris et al.11 Coagulation and the vessel wall in thrombosis and atherosclerosis 6
9 Adamczyk et al.12 Biomarkers of calcification and atherosclerosis in patients with degenerative aortic 
stenosis in relation to concomitant coronary artery disease
6
10 Janda et al.13 Osteoprotegerin as a marker of cardiovascular risk in patients on peritoneal dialysis 6
11 Opolski et al.14 Cardiovascular therapy, diagnostic procedures, and control of risk factors in patients 
with diabetes or coronary artery disease in Poland: the Kardia-Pol registry
6
12 Stróżecki et al.15 Advanced glycation end products and arterial stiffness in patients with diabetic 
nephropathy and patients with chronic kidney disease without diabetes
6
TABLE 3 Most cited papers published in 2014
No. Article Title Total citations
1 Ratajczak et al.16 New advances in stem cell research: practical implications for regenerative medicine 7
2 Cieslik‑Guerra et al.17 Correlation between the activity of the autonomic nervous system and endothelial 
function in patients with acute coronary syndrome
5
3 Undas et al.18 Practical aspects of new oral anticoagulant use in atrial fibrillation 5
4 Nicolini et al.19 Noninvasive ventilation for hypercapnic exacerbation of chronic obstructive pulmonary 
disease: factors related to noninvasive ventilation failure
4
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we cordially invite you to submit your manuscripts 
to our journal, which guarantees a rapid peer re‑
view and quick publication after acceptance.
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